Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moroctocog alfa (AF-CC) Prophylaxis in Children with Hemophilia A
NCT00543439Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2007
- Primary completion
- Apr 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, open-label trial of moroctocog alfa in hemophilia A (2 arms), sponsored by Pfizer. Primary endpoint: Annualized Bleed Rate at 18 months. Started Dec 2007; status: completed.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00543439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00543439.